Amphastar Pharmaceuticals Long-Term Debt 2011-2026 | AMPH

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Amphastar Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
620 M	602 M	590 M	72.8 M	74.8 M	34.2 M	39.4 M	32 M	40.8 M	32.4 M	30.2 M	36.1 M	10.1 M	16 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
620 M	10.1 M	159 M

Quarterly Long-Term Debt Amphastar Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
609 M	608 M	604 M	602 M	596 M	587 M	-	590 M	653 M	-	72.9 M	72.8 M	-	73.9 M	74.3 M	74.8 M	75.6 M	30.5 M	32.3 M	45.9 M	34.2 M	34.2 M	34.2 M	46.3 M	39.4 M	39.4 M	39.4 M	49.1 M	32 M	32 M	32 M	45.7 M	40.8 M	40.8 M	40.8 M	36 M	32.4 M	32.4 M	32.4 M	40.3 M	30.2 M	30.2 M	30.2 M	42.7 M	36.1 M	36.1 M	36.1 M	10.1 M	10.1 M	10.1 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
653 M	10.1 M	137 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	755 K	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	31 K	-	5.93 %	$ 314 M	Canada
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	173 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	9.62 M	-	-0.23 %	$ 916 M	USA
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
REGENXBIO RGNX	65.2 M	$ 8.39	-0.83 %	$ 433 M	USA
Aileron Therapeutics ALRN	69 K	-	10.36 %	$ 9.8 M	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Cabaletta Bio CABA	2.88 M	$ 2.79	0.18 %	$ 280 M	USA
Applied Genetic Technologies Corporation AGTC	9.12 M	-	-	$ 26.5 M	USA
Rigel Pharmaceuticals RIGL	52.5 M	$ 26.27	-0.08 %	$ 473 M	USA
AgeX Therapeutics AGE	2.95 M	-	-10.17 %	$ 12.2 K	USA
Aptinyx APTX	22.1 M	-	-39.0 %	$ 4.57 M	USA
Acorda Therapeutics ACOR	167 M	-	-24.86 %	$ 820 K	USA
Esperion Therapeutics ESPR	653 K	$ 2.88	4.35 %	$ 599 M	USA
Acasti Pharma ACST	410 K	-	4.01 %	$ 150 M	Canada
Equillium EQ	356 K	$ 2.08	0.97 %	$ 119 M	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
Adverum Biotechnologies ADVM	86 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	146 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	8.14 M	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	1.33 M	-	-	$ 7.46 M	Israel
Avenue Therapeutics ATXI	2.03 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	47.9 M	$ 1.33	-0.38 %	$ 339 M	Britain
Atreca BCEL	60.3 M	-	-11.76 %	$ 5.79 M	USA
BeiGene, Ltd. BGNE	962 M	-	0.49 %	$ 251 B	Cayman-islands
Relay Therapeutics RLAY	42.8 M	$ 9.87	2.81 %	$ 1.41 B	USA
bluebird bio BLUE	37.7 M	-	-	$ 546 M	USA
BioDelivery Sciences International BDSI	78.5 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	6.09 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	4.72 M	-	-	$ 3.74 B	USA
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Avid Bioservices CDMO	54.2 M	-	-	$ 789 M	USA
CureVac N.V. CVAC	25.4 M	-	-	$ 867 M	Germany
Bellerophon Therapeutics BLPH	203 K	-	-74.18 %	$ 955 K	USA
Avidity Biosciences RNA	45.3 M	$ 13.12	0.23 %	$ 1.81 B	USA
CRISPR Therapeutics AG CRSP	188 M	$ 48.11	2.17 %	$ 4.33 B	Schweiz
Arbutus Biopharma Corporation ABUS	806 K	$ 4.54	0.11 %	$ 870 M	Canada
AIkido Pharma AIKI	2.63 M	-	1.93 %	$ 17.4 M	USA
Royalty Pharma plc RPRX	8.57 B	$ 47.33	0.64 %	$ 20.3 B	USA
Allakos ALLK	38.2 M	-	-	$ 28.6 M	USA
Brickell Biotech BBI	146 K	-	-5.38 %	$ 6.06 M	USA